Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

被引：20

作者：

Uckun, Fatih M. ^{[1
,2
]}

Qazi, Sanjive ^{[3
]}

机构：

[1] Childrens Hosp Los Angeles, Dev Therapeut Program, Inst Pediat Clin Res, Los Angeles, CA 90027 USA

[2] Univ So Calif, Dept Pediat, Div Hematol Oncol, Sch Med,Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA

[3] Gustavus Adolphus Coll, St Peter, MN 56082 USA

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2010年 / 10卷 / 09期

关键词：

leukemia; lymphoma; nanotechnology; rational drug design; RNA interference; spleen tyrosine kinase; tyrosine kinase inhibitor; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL ANTIGEN RECEPTOR; CHILDRENS-ONCOLOGY-GROUP; PRIMARY CLONOGENIC BLASTS; NON-HODGKIN-LYMPHOMA; BONE-MARROW RELAPSE; B-CELLS; PHOSPHOINOSITIDE; 3-KINASE; APOPTOTIC RESISTANCE; THERAPEUTIC TARGET;

D O I：

10.1586/ERA.10.112

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Spleen tyrosine kinase (SYK) has emerged as a potential molecular target for the treatment of B-lineage leukemias and lymphomas. Here, we provide an overview of the current state of knowledge regarding the regulatory signaling function of SYK and its role in the pathogenesis of B-lineage lymphoid malignancies, available methods and drug candidates for targeting SYK, as well as compelling preclinical and clinical evidence regarding the clinical potential of inhibiting SYK. The further development of rationally designed SYK inhibitors may provide the foundation for therapeutic innovation against B-lineage leukemias and lymphomas.

引用

页码：1407 / 1418

页数：12

共 50 条

[41] TREATMENT OF CHRONIC FORMS OF MALIGNANT LYMPHOMAS AND LEUKEMIAS
CRAVER, LF
MEDICAL CLINICS OF NORTH AMERICA, 1949, (NNATI) : 527 - 540
[42] LYMPHOMAS AND LEUKEMIAS - THE VALUE OF EARLY DIAGNOSIS AND TREATMENT
CRAVER, LF
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1948, 136 (04): : 244 - 249
[43] A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment
Heidari, Amirhossein
Ghane, Yekta
Heidari, Nazila
Sadeghi, Sara
Goodarzi, Azadeh
INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
[44] TRIETHYLENE MELAMINE IN THE TREATMENT OF CERTAIN LYMPHOMAS AND LEUKEMIAS
BURTNER, OW
JENSEN, LC
AMERICAN JOURNAL OF MEDICINE, 1951, 11 (05): : 621 - 621
[45] TREATMENT OF LEUKEMIAS AND LYMPHOMAS WITH MONOCLONAL-ANTIBODIES
MILLER, RA
MALONEY, D
STRATTE, P
LEVY, R
HYBRIDOMA, 1983, 2 (02): : 238 - 238
[46] Purine Nucleoside Phosphorylase (PNP): A novel target leukemias and lymphomas
Kantarjian, Hagop M.
SEMINARS IN ONCOLOGY, 2007, 34 (06) : S1 - S2
[47] c-Met receptor tyrosine kinase: A novel molecular therapeutic target for the treatment of pancreatic cancer
Jagadeeswaran, Ramasamy
Ahmed, Salman
Janamanchi, Varalakshmi
Surawska, Hanna
Karikari, Collins
Maitra, Anirban
Salgia, Ravi
CANCER RESEARCH, 2006, 66 (08)
[48] Spleen Tyrosine Kinase (SYK) Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia
Buchner, Maike
Fuchs, Simon
Prinz, Gabriele
Pfeifer, Dietmar
Bartholome, Kilian
Chevalier, Nina
Vallat, Laurent
Timmer, Jens
Gribben, John G.
Jumaa, Hassan
Veelken, Hendrik
Dierks, Christine
Zirlik, Katja
BLOOD, 2008, 112 (11) : 203 - 203
[49] Spleen Tyrosine Kinase Inhibitors (SYK) as Potential Treatment for Autoimmune and Inflammatory Disorders
Abdel-Magid, Ahmed F.
ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (01): : 18 - 19
[50] Molecular target-based cancer therapy: tyrosine kinase inhibitors
Kenji Tamura
Masahiro Fukuoka
International Journal of Clinical Oncology, 2003, 8 (4) : 207 - 211

← 1 2 3 4 5 →